Clinical Advances in Atopic Dermatitis: Novel
Therapies for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.


This activity is valid from January 31, 2017 to January 31, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
Genzyme, a Sanofi company & Regeneron Pharmaceuticals and Pfizer, Inc.

Description:
Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Current atopic dermatitis treatments attempt to reduce inflammation and itchiness to maintain the protective integrity of the skin and have shown the ability to manage the disease in the short term, but have had troubles with long term efficacy. Fortunately several new treatments, including novel monoclonal antibodies or targeted therapies, have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life.

Upon Completion of this activity, participants will be able to:

  • Compare and contrast the safety, efficacy and mechanisms of action of emerging therapies in the management of moderate-to-severe atopic dermatitis (AD)

  • Analyze recent late stage clinical trial data on novel therapies for patients with moderate-to-severe AD

  • Examine the role of pathophysiology on the development of new and emerging therapies for AD

  • Discuss challenges clinicians encounter when managing moderate-to-severe AD and discuss evidence-based strategies to overcome these barriers

  • Review the role of PDE-4 inhibition in the management of AD

  • Explore the differences between mild-to-moderate AD and moderate-to-severe AD and how the treatment options and management strategies differ in each setting
     

Faculty: Lawrence F. Eichenfield, MD
Professor of Dermatology and Pediatrics
Chief, Pediatric and Adolescent Dermatology
University of California, San Diego and
Rady Children's Hospital, San Diego

Disclosure:

Dr. Eichenfield receives honoraria for consultant, advisory board or speaker engagement from Anacor, Celgene, Genentech, Otsuka, Regeneron and Valeant. He is compensated with equity options for consulting with TopMD. He serves as an investigator with no compensation for Astellas Pharma US and Regeneron. His presentation has been peer reviewed.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This educational activity is supported by educational grants from
Genzyme, a Sanofi company & Regeneron Pharmaceuticals and Pfizer, Inc.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue